GP Pharm, the pharmaceutical company of the Lipotec Group, specialises in the research, development, production...
Last January, GCC-DR (Gulf Central Committee for Drug Registration) granted a Registration Certificate of Manufacturing Site to GP Pharm.
This certificate is valid for the next five years, allowing GP Pharm to manufacture drug products for the region. The GCC-DR certificate covers authorisation in Saudi Arabia, Kuwait, Bahrain, Qatar, the United Arab Emirates, and the Sultanate of Oman.
GP Pharm owns a state-of-the-art manufacturing site located in Sant Quintí de Mediona (Barcelona, Spain) on 30,000m² of land. At this site GP Pharm has the capability to produce drug products for injection using cytotoxic and high potency products. Additionally, GP Pharm produces at industrial-scale drug delivery formulations for injection such liposomes and microspheres.
This approval complements other currently valid manufacturing authorisations (GMP):
- AEMPS (Spanish Health Agency) – Europe 
- PMDA – Japan 
- TGA – Australia 
- PHAC – Canada 
The next step for the company consists of obtaining authorisation by the FDA. During 2011 GP Pharm plans to apply for its first FDA inspection, which would allow the company to enter the US market with products manufactured at its site.
For the eighth consecutive year GP Pharm will be present at CPhI, the world's most...
GP Pharm Expands its Pharmaceutical Line Against Advanced Colorectal Cancer with Oxaliplatin and Irinotecan 300mg and 500mg
GP Pharm has started the commercialisation of Oxaliplatin and Irinotecan 300mg and 500mg, drugs to...
PHOENIX Study Proposes Integration Measures Between the Financial World and Biotechnological Companies
CataloniaBIO has launched the PHOENIX Study to get the financial world's vision about the sector...